|
|
 |
 |
104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft 2006
Abstract
Abstract
SA.01.08 Results of intravitreal injection of Bevacizumab (Avastin®) in exudative age-related macular degeneration Burau H., Struebin I., Feltgen N., Hansen L. L., Agostini H. T.
Universitäts-Augenklinik Freiburg Objective: For some time the intravitreal injection of bevacizumab (Avastin®), an antibody against VEGF, is used as a therapeutic alternative in patients with exsudative age-related macular degeneration (AMD). The purpose of this study was to evaluate the effect this treatment in cases of AMD without alternative therapeutic options.
Methods: In this interventional pilot study a total of 25 eyes of 25 patients with occult choroidal neovascularisation (13 with pigment epithelium detachment (PED)) were included. Either there were no established therapeutic alternatives or previous treatment did not stabilize the course of AMD in this patients. Patients received intravitreal bevacizumab (1,0 mg in 0,05 ml) on a 6-week basis and had ophthalmic examinations 1 and 4 weeks later, which included VA (ETDRS), optical coherence tomography (OCT) and fluorescein angiography. Treatment was discontinued when there was no leakage in the fluorescein angiography or when neither angiographic findings nor visual acuity changed.
Results: The observation period covered a period of 4 weeks to 4 month. No significant side effects were observed besides sicca symptoms in the treated eye in 5 patients the day after the injection. All patients had a stabilization of VA (no decrease of VA above 3 lines, no increase above 2 lines). In the whole group 1 patient had a decrease of 2 lines, 6 patients a decrease of 1 line, 6 patients had an unchanged VA, 10 patients an improvement of 1 line, 2 patients an improvement of 2 lines. In the group with PED (n=13) 3 patients had a decrease of 1 line, 2 patients had unchanged VA, 8 patients had an improvement of 1 line.
Conclusions: This short-term results suggest that intravitreal injection of bevacizumab is a well tolerated therapeutic alternative in patients with exsudative AMD (especially with PED) when no established therapy is applicable. However, no conclusion about the long-term effects or the duration of the necessary treatment with bevacizumab can be drawn.
Zurück | Back
|
